| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00975325 | Erectile Dysfunction | Drug: Yohimbine|Drug: Yohimbine | Walter Ritter GmbH & Co | Phase 4 | 2009-10-01 | 2015-06-25 |
| NCT01593215 | Type 2 Diabetes | Drug: Yohimbine | Anders Rosengren, MD PhD|Region Skane|Lund University | Phase 2 | 2012-05-01 | 2015-01-07 |
| NCT00078715 | Depression, Involutional|Major Depresssion | Drug: Yohimbine hydrochloride|Drug: Placebo | National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC) | Phase 2 | 2004-03-01 | 2012-08-16 |
| NCT00958880 | Social Anxiety Disorder | Behavioral: Group Cognitive Behavioral Therapy|Drug: Yohimbine Hydrochloride|Drug: Sugar Pill | Southern Methodist University | Phase 3 | 2009-03-01 | 2013-09-06 |
| NCT00734422 | Phobic Disorders | Behavioral: Virtual Reality Exposure Therapy | VU University of Amsterdam | Phase 2|Phase 3 | 2008-07-01 | 2011-08-03 |
| NCT00217048 | Healthy Volunteers | Drug: Yohimbine, oral | Mayo Clinic|National Institutes of Health (NIH) | Phase 1|Phase 2 | 2005-06-01 | 2009-04-27 |
| NCT01031979 | Post-Traumatic Stress Disorder | Drug: Yohimbine|Drug: Placebo | VA Office of Research and Development | Phase 2 | 2010-12-01 | 2017-01-03 |
| NCT00042536 | Erectile Dysfunction | Drug: Naltrexone HCL/ Yohimbine HCL | National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC) | | 2002-07-01 | 2008-03-03 |
| NCT00814047 | Blood Flow Velocity|Autoregulation|Ocular Physiology | Drug: Yohimbine hydrochloride | Medical University of Vienna | Phase 4 | | 2008-12-22 |
| NCT00535002 | Cocaine Related Disorders | Drug: Yohimbine|Drug: Placebo | Medical University of South Carolina|National Institute on Drug Abuse (NIDA)|Office of Research on Women's Health (ORWH) | | 2007-09-01 | 2013-03-27 |
| NCT01536925 | Heroin Dependence|Opioid-Related Disorders | Wayne State University|National Institute on Drug Abuse (NIDA) | | 2011-12-01 | 2016-11-01 |
| NCT00605904 | Alcoholism | Drug: Acamprosate|Drug: Yohimbine|Drug: mCPP|Drug: Saline | National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC) | Phase 2 | 2008-01-01 | 2012-05-23 |
| NCT02963181 | Hypotension, Orthostatic|Hypertension|Autonomic Nervous System Diseases | Drug: Yohimbine|Drug: Melatonin | Lawson Health Research Institute | Early Phase 1 | 2017-01-01 | 2016-11-14 |
| NCT02578849 | Parkinsons Disease | Drug: L-DOPA | Aarhus University Hospital|University of Copenhagen | | 2012-01-01 | 2015-10-15 |
| NCT00032838 | Healthy | Drug: Yohimbine | National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC) | | 2002-03-01 | 2008-03-03 |
| NCT02470026 | Major Depressive Disorder|Early Life Trauma | Drug: yohimbine|Drug: placebo | Charite University, Berlin, Germany | | 2014-06-01 | 2016-01-27 |
| NCT00029627 | Healthy | Drug: Yohimbine | National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC) | | 2002-01-01 | 2008-03-03 |
| NCT00709956 | Pulmonary Arterial Hypertension | Drug: iloprost (5 g)|Drug: placebo | Actelion | Phase 3 | 2008-07-01 | 2015-09-10 |
| NCT00709098 | Pulmonary Arterial Hypertension | Drug: iloprost|Drug: iloprost | Actelion | Phase 3 | 2008-09-01 | 2015-09-10 |
| NCT02007694 | Phobic Disorders | Behavioral: Virtual Reality Exposure Therapy (VRET) | VU University of Amsterdam | Phase 2|Phase 3 | 2013-03-01 | 2015-07-06 |
